Medicines For Europe Sets Out Trade Agenda
Responds To European Commission’s Trade Strategy Announcement
Medicines for Europe has responded to a European Commission announcement on the EU’s international trade strategy by setting out its priorities in this area for the pharmaceutical sector, including improved international collaboration on supply chain security as well as stronger co-operation in the field of intellectual property.
You may also be interested in...
A host of European pharmaceutical industry associations, including off-patent body Medicines for Europe, has urged EU trade ministers to push back against European and global restrictions on the movement of medicines and medical equipment that are hampering the international supply chain's response to the coronavirus pandemic.
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.